Good morning :)
$
₹
B

BridgeBio Oncology Therapeutics, Inc.

BBOT

NASDAQ
B

BridgeBio Oncology Therapeutics, Inc.

BBOT

NASDAQ
$2.290.94% (-0.02)
$
₹
$2.290.94% (-0.02)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $185.2M the stock is ranked 4281

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.65
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.07
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 12 analysts reports

Buy
12 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+914.89%

Earnings Growth

+97.2%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.67
50.67
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.90
28.90
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
32.21
32.21
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.24
21.24
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

2026
Current$2.32Baseline
Analyst Target - 1 year
Target$23.55+914.89%

All values in $

20232024202520262027$8.04$14.00$19.95Target+914.89%
2026
Current$2.32Baseline
Analyst Target - 1 year
Target$23.55+914.89%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-101.98Baseline
Forecast for Dec 2026
High$-1.98+98.06%
Average$-2.86+97.2%
Low$-4.61+95.48%

All values in $

20222023202420252026N/AN/A0.32-101.98Low+95.48%Average+97.2%High+98.06%
2025
Current$-101.98Baseline
Forecast for Dec 2026
High$-1.98+98.06%
Average$-2.86+97.2%
Low$-4.61+95.48%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-44.7
-38.7
-42.1
-56.4
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0000000000
Net Income-15.44-21.82-17.32-19.68-22.05-28.43-44.75-38.79-42.10-56.45
Net Profit Margin----------
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
BridgeBio Oncology Therapeutics, Inc. -0.65-
AbbVie Inc50.6750.450.60
Amgen Inc28.9021.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare BBOT with any stock or ETF
Compare BBOT with any stock or ETF
Comparing from
BBOT
ABBV
AMGN
Loading...

Frequently asked questions

  1. BridgeBio Oncology Therapeutics, Inc. (BBOT) share price today is $2.29 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $2.39 and a day low of $2.22.

  2. BridgeBio Oncology Therapeutics, Inc. stock trades on NASDAQ under the ticker symbol BBOT.

  3. BridgeBio Oncology Therapeutics, Inc.'s market capitalization is $185.2M as of November 5, 2026 at 2:29 AM IST.

  4. BridgeBio Oncology Therapeutics, Inc.'s price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. BridgeBio Oncology Therapeutics, Inc.'s price-to-book (P/B) ratio is 0.65 as of November 4, 2026.

  6. Yes, You can buy BridgeBio Oncology Therapeutics, Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy BridgeBio Oncology Therapeutics, Inc. shares in three steps: 1. Search BridgeBio Oncology Therapeutics, Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since BridgeBio Oncology Therapeutics, Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in BridgeBio Oncology Therapeutics, Inc. (BBOT) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 4.3516 shares at the current price of $2.29.

Loading...